soblidotin + gemcitabine

Soblidotin + gemcitabine is an experimental combination chemotherapy regimen consisting of the dolastatin 10 derivative soblidotin and the nucleoside analog gemcitabine. Soblidotin (also known as TZT-1027) is a small molecule antimicrotubule agent that binds to beta-tubulin, inhibiting polymerization and inducing G2/M phase cell cycle arrest and apoptosis. Gemcitabine is a pyrimidine antimetabolite that inhibits DNA synthesis by acting as a nucleoside analog and inhibiting ribonucleotide reductase. The combination was investigated by Daiichi Sankyo in a Phase I clinical trial (NCT00072228) for patients with locally advanced or metastatic solid tumors. However, the trial was withdrawn before completion, and development of this specific combination has been discontinued.

Brand names

Gemzar

Other names

soblidotin and gemcitabineTZT-1027 + gemcitabine